An interventional study of Dyadic Case Management in HIV, Pre-exposure Prophylaxis and Case Management, sponsored by University of Chicago. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by University of Chicago · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The overall goal of this study is to test whether dyadic and focused case management coupled with contingency management will (1) improve financial wellbeing, (2) improve access to food, (3) increase linkage and retention rates for individuals living with HIV or those taking PrEP (PrEP persistence), and (4) increase the proportion of individuals living with HIV who are virally suppressed (viral suppression) when compared to routine Ryan White Non-Medical Case Management.
The purpose of this research is to test the impact of dyadic, focused case management coupled with contingency management on financial well-being, access to food, linkage to and retention in care outcomes for individuals living with or vulnerable to HIV.
The study team will be testing the hypotheses that dyadic case management that is focused on financial wellness coupled with contingency management, will have better outcomes for folks living with or vulnerable to HIV. Analyses will be used to assess the efficacy of the intervention as an emerging practice.
University of Chicago is the lead sponsor of 926 studies on the registry; 187 are open to participants now.
Of its 103 completed or terminated interventional studies of FDA-regulated products, 72 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Gap in or PrEP care access in the past 24 months, defined as a gap greater than 6 months or detectable viral load at least one time in the past 24 months
Self-reported financial or food insecurity
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be offered the current standard of care, Ryan White Non-Medical Case Management. Case management services are need focused and contact is client initiated.
Participants will receive dyadic case management, specifically they will have two case managers assigned to their case. Case management services will be goal focused and will utilize components from Appreciative Inquiry to orient work to future planning, goals, and financial stability.
Behavioral: Dyadic Case Management
Subjects enrolled in the intervention arm will be offered focused case management centered around goal setting and future orientation. Subjects will be assigned two case managers to support their goals. Clients will receive conditional cash transfers for medical visit attendance and negative HIV/syphilis tests or undetectable viral loads.
Financial wellbeing
Proportion of subjects who report improved financial wellbeing (e.g. consistent income, ability to pay bills).
Time frame: 18 months
Food Security
Proportion of individuals who report improved access to food (e.g. fewer gaps in access to food, reduced concern about access to food).
Time frame: 18 months
PrEP Persistence
Proportion of individuals who have engaged in PrEP care regularly (beyond 6 months).
Time frame: 18 months
Viral Suppression
Proportion of individuals who have a viral load below 200 copies/mL
Time frame: 18 months
Plan to share: No
Started Sep 2022 (actual). Primary completion is estimated for Nov 2026, 50 months after the start.
Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 19, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.